Two Sigma Securities’s Pacira BioSciences PCRX Stock Holding History

Two Sigma Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,644	Closed	-$212K	–	1090
2017 Q1	$212K	Sell	4,644 -1,878	-29%	-$81.2K	0.04%	614
2016 Q4	$211K	Buy	+6,522	New	+$218K	0.07%	424
2016 Q3	–	Sell	-13,392	Closed	-$452K	–	758
2016 Q2	$452K	Buy	+13,392	New	+$658K	0.25%	114

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Two Sigma Securities's PCRX Position: Q2 2017 in Review

Two Sigma Securities sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 4,644 shares — an estimated $212K sold.

Two Sigma Securities first reported a position in PCRX in Q2 2016 and held it in 3 quarters. The position peaked at $452K in Q2 2016. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

Two Sigma Securities reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
Two Sigma Securities sold 4,644 Pacira BioSciences shares in Q2 2017, an estimated $212K.
Two Sigma Securities first reported a position in Pacira BioSciences in Q2 2016 and held it in 3 quarters.
Two Sigma Securities's Pacira BioSciences position peaked at $452K in Q2 2016.
196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Two Sigma Securities's 13F filing for Q2 2017, filed 14 Aug 2017.